Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16926223rdf:typepubmed:Citationlld:pubmed
pubmed-article:16926223lifeskim:mentionsumls-concept:C0278488lld:lifeskim
pubmed-article:16926223lifeskim:mentionsumls-concept:C0332174lld:lifeskim
pubmed-article:16926223lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:16926223lifeskim:mentionsumls-concept:C0671970lld:lifeskim
pubmed-article:16926223lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:16926223lifeskim:mentionsumls-concept:C1708063lld:lifeskim
pubmed-article:16926223pubmed:issue27lld:pubmed
pubmed-article:16926223pubmed:dateCreated2006-9-19lld:pubmed
pubmed-article:16926223pubmed:abstractTextThe taxanes and capecitabine have synergistic antitumor activity in preclinical models. This trial was designed to determine the efficacy and tolerability of weekly paclitaxel plus capecitabine as first-line treatment for metastatic breast cancer (MBC).lld:pubmed
pubmed-article:16926223pubmed:languageenglld:pubmed
pubmed-article:16926223pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16926223pubmed:citationSubsetIMlld:pubmed
pubmed-article:16926223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16926223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16926223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16926223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16926223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16926223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16926223pubmed:statusMEDLINElld:pubmed
pubmed-article:16926223pubmed:monthSeplld:pubmed
pubmed-article:16926223pubmed:issn1527-7755lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:O'Shaughnessy...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:AsmarLinaLlld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:DeesE...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:NeubauerMarcu...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:BlumJoanne...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:BoehmKristi...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:IlegboduDesDlld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:McMahonRichar...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:ChackoAparnaAlld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:DoaneLisaLlld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:EthirajanSuku...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:HopkinsJudith...lld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:MertenSuzanSlld:pubmed
pubmed-article:16926223pubmed:authorpubmed-author:NegronAngelAlld:pubmed
pubmed-article:16926223pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16926223pubmed:day20lld:pubmed
pubmed-article:16926223pubmed:volume24lld:pubmed
pubmed-article:16926223pubmed:ownerNLMlld:pubmed
pubmed-article:16926223pubmed:authorsCompleteYlld:pubmed
pubmed-article:16926223pubmed:pagination4384-90lld:pubmed
pubmed-article:16926223pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:meshHeadingpubmed-meshheading:16926223...lld:pubmed
pubmed-article:16926223pubmed:year2006lld:pubmed
pubmed-article:16926223pubmed:articleTitlePhase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.lld:pubmed
pubmed-article:16926223pubmed:affiliationUS Oncology Research Inc, Houston, USA. joanne.blum@usoncology.comlld:pubmed
pubmed-article:16926223pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16926223pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16926223pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16926223pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16926223lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16926223lld:pubmed